

Appl. No. 09/533,798
Amdt. dated October 13, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1648

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-8 (Canceled)

9. (Currently amended) A vaccine composition comprising a non-human, mammalian 5T4 antigen as an immunizing agent, and a pharmaceutically acceptable carrier.

10. (Previously presented) The vaccine composition according to claim 9, further comprising one or more adjuvants.

11. (Currently amended) The vaccine composition according to claim 9, wherein the 5T4 antigen is [[a]] modified to differ from a naturally occurring mammalian 5T4 antigen, and comprises ~~comprising~~ a peptide epitope of a mammalian 5T4 antigen, and wherein ~~said~~ the modified 5T4 antigen induces a CTL response.

12. (Currently amended) A method for eliciting an anti-tumor immunotherapeutic response to a tumor in a subject, comprising immunizing the subject with a mammalian 5T4 antigen, wherein the 5T4 antigen induces an anti-tumor immunotherapeutic response to a tumor in the subject.

13. (Canceled)

14. (Currently amended) The method according to claim 12, wherein the 5T4 antigen is [[a]] modified to differ from a naturally occurring mammalian 5T4 antigen and comprises ~~comprising~~ an HLA CTL peptide epitope of a mammalian 5T4 antigen, and wherein said anti-tumor immunotherapeutic response comprises a CTL response.

Appl. No. 09/533,798
Amdt. dated October 13, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1648

PATENT

15. (Canceled)

16. (Previously presented) The method according to claim 12, wherein the anti-tumor immunotherapeutic response comprises an antibody response.

17-45. (Canceled)

46. (Currently amended) An anti-tumor immunotherapeutic vaccine composition, comprising a ~~modified~~ 5T4 antigen modified to differ from a naturally occurring mammalian 5T4 antigen and a pharmaceutically acceptable carrier, wherein ~~said the~~ modified 5T4 antigen comprises an HLA CTL peptide epitope of ~~unmodified a~~ mammalian 5T4 antigen.

47. (Currently amended) The vaccine composition according to claim 46, wherein said ~~modified~~ naturally occurring mammalian 5T4 antigen is a human ~~modified~~ 5T4 antigen.

48. (Previously presented) The vaccine composition according to claim 9, wherein said non-human, mammalian 5T4 antigen is a murine antigen.

49. (Previously presented) The vaccine composition according to claim 9, wherein said non-human, mammalian 5T4 antigen is a canine antigen.

50. (Currently amended) The vaccine composition according to claim 46, wherein said the modified 5T4 antigen comprises a peptide sequence selected from the group consisting of:

- (a) FLTGNQLAV (SEQ ID NO:5);
- (b) ALIGAIPLL (SEQ ID NO:6);
- (c) SLQTSYVFL (SEQ ID NO:7);
- (d) AIFLLVLYL (SEQ ID NO:8);
- (e) GLPHIRVFL (SEQ ID NO:9);
- (f) FLGIVLALI (SEQ ID NO:10);

Appl. No. 09/533,798
Amdt. dated October 13, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1648

PATENT

- (g) NLTEVPTDL (SEQ ID NO: 11);
- (h) NLFLTGNQL (SEQ ID NO:12);
- (i) FLYLPRDVL (SEQ ID NO:13);
- (j) VLYLNRKGI (SEQ ID NO:14);
- (k) LIGAIPLL (SEQ ID NO:15);
- (l) FLDNNPWVC (SEQ ID NO:16); and
- (m) HMADMVTWL (SEQ ID NO: 17).

51. (Currently amended) The vaccine composition according to claim 46, wherein ~~said~~ the modified 5T4 antigen comprises a peptide sequence selected from the group consisting of:

- (a) YMADMVAWL (SEQ ID NO:18);
- (b) NLLEVPADL (SEQ ID NO:19);
- (c) FLTGNQMTV (SEQ ID NO:20);
- (d) ALIGAIPLL (SEQ ID NO:21);
- (e) FLFLPRDLL (SEQ ID NO:22);
- (f) SLQTSYVFL (SEQ ID NO:23);
- (g) AIFLLVLYL (SEQ ID NO:24);
- (h) GLAHVKVFL (SEQ ID NO:25);
- (i) FLGIVLALI (SEQ ID NO:26); and
- (j) VLYLNRKG (SEQ ID NO:27).

52. (Currently amended) The method according to claim 12, wherein the 5T4 antigen is ~~[[a]]~~ modified to differ from a naturally occurring mammalian 5T4 antigen.